Kamada Ltd.(KMDA)Earnings, Financials & Key Ratios
KMDA•NASDAQ
$7.31
19.8× P/E·Price updated Jul 7, 2026
AboutKamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Show more
- Revenue$180M+12.1%
- EBITDA$41M+21.5%
- Net Income$20M+39.7%
- EPS (Diluted)0.37+48.0%
- Gross Margin42.34%-2.6%
- EBITDA Margin22.8%+8.4%
- Operating Margin14.54%+16.7%
- Net Margin11.19%+24.6%
- ROE7.64%+33.0%
KMDA Price & Volume
Kamada Ltd. (KMDA) stock price & volume — 10-year historical chart
Loading chart...
Operational Volatility Masks Strategic Biologics Transition
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Geopolitical manufacturing supply disruption
Key Thesis Takeaways
- Kamada is navigating a complex transition toward a royalty-heavy revenue model, though its financial performance remains hampered by lumpy growth and significant working capital swings.
- While the company maintains a robust liquidity position with a current ratio of 3.33, investors should remain cautious regarding the impact of geopolitical risks on its Israel-based manufacturing hub.
- Future upside depends on the company's ability to stabilize operating margins, which have fluctuated between 7.6% and 17.7% over the last ten quarters, while managing the inherent risks of its specialized fractionation business.
Verdict Logic
while the company's minimal debt-to-equity ratio of 0.04 offers financial safety, the extreme volatility in free cash flow margins and the $12.1 million working capital drain in 2026Q1 warrant a wait-and-see approach.
KMDA Growth Metrics
Kamada Ltd. (KMDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.92%
5 Years6.25%
3 Years11.74%
TTM8.64%
Profit CAGR
10 Years-
5 Years3.34%
3 Years-
TTM26.8%
EPS CAGR
10 Years-
5 Years-2.03%
3 Years-
TTM20.34%
Return on Capital
10 Years6.9%
5 Years3.9%
3 Years6.02%
Last Year8.02%
KMDA Recent Earnings
Kamada Ltd. (KMDA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.07-41.7%
$0.12
Rev
$45M-3.2%
$47M
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.06-33.3%
$0.09
Rev
$45M-1.6%
$45M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.09-10.0%
$0.10
Rev
$47M-68.1%
$148M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.13+44.4%
$0.09
Rev
$45M-71.1%
$155M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.07vs $0.12-41.7% | $45Mvs $47M-3.2% |
| Q2 2026 | Mar 11, 2026 | $0.06vs $0.09-33.3% | $45Mvs $45M-1.6% |
| Q4 2025 | Nov 10, 2025 | $0.09vs $0.10-10.0% | $47Mvs $148M-68.1% |
| Q3 2025 | Aug 13, 2025 | $0.13vs $0.09+44.4% | $45Mvs $155M-71.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Kamada Ltd. (KMDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.31 | $421.69M | 19.76 | 12.12% | 11.19% | 7.64% | 2.93% | |
| $9.21 | $2.13B | 15.35 | 19.63% | 32.43% | 38.97% | — | |
| $7.21 | $6.1B | 11.07 | 0.2% | 5.58% | 5.43% | — | |
| $292.50 | $7.9B | 10.50 | 0.65% | 6.52% | 2.4% | — | |
| $15.55 | $1.65B | -2.27 | — | — | -866.46% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — |
Compare KMDA vs Peers
Kamada Ltd. (KMDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when KMDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KMDA Frequently Asked Questions
Kamada Ltd. (KMDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Kamada Ltd.'s revenue?
Kamada Ltd. (KMDA) reported $181.7M in revenue for fiscal year 2025. This represents a 1094% increase from $15.2M in 2008.
How fast is Kamada Ltd. growing?
Kamada Ltd. (KMDA) grew revenue by 12.1% over the past year. This is steady growth.
Is KMDA profitable?
Yes, Kamada Ltd. (KMDA) is profitable, generating $20.4M in net income for fiscal year 2025 (11.2% net margin).
Dividend & Returns
Does KMDA pay dividends?
Yes, Kamada Ltd. (KMDA) pays a dividend with a yield of 2.93%. This makes it attractive for income-focused investors.
What is KMDA's return on equity?
Kamada Ltd. (KMDA) has a return on equity (ROE) of 7.6%. This is below average, suggesting room for improvement.
What is Kamada Ltd.'s free cash flow?
Kamada Ltd. (KMDA) generated $16.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.